SLNCF Silence Therapeutics plc

Nasdaq Pharmaceutical Preparations X0 CIK: 0001479615
AI RATING
STRONG_SELL
95% Confidence

Investment Thesis

Company experiencing catastrophic business deterioration with 98.7% revenue collapse and -62.3M annual operating cash burn against only 11.3M cash reserves (~2 months runway). Massive operating losses of -91.1M indicate fundamental product/business failure with no visible path to profitability.

Strengths

  • + Zero debt burden provides financial flexibility
  • + Positive gross margin of 61.5% on remaining product sales
  • + Stockholders equity of 62.3M provides book value cushion

Risks

  • ! Critical cash runway of ~2 months at current -62.3M annual burn rate
  • ! 98.7% YoY revenue collapse suggests loss of primary product or failed pipeline
  • ! Operating losses of -91.1M unsustainable relative to 559K revenue base
  • ! No evidence of near-term catalysts for revenue recovery or profitability

Key Metrics to Watch

Financial Metrics

Revenue
559.0K
Net Income
-88.6M
EPS (Diluted)
$-0.63
Free Cash Flow
-62.3M
Total Assets
131.4M
Cash
11.3M

Profitability Ratios

Gross Margin 61.5%
Operating Margin -16,292.8%
Net Margin -15,851.9%
ROE -142.2%
ROA -67.4%
FCF Margin -11,149.6%

Balance Sheet & Liquidity

Current Ratio
8.72x
Quick Ratio
8.72x
Debt/Equity
0.00x
Debt/Assets
52.6%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-04-16T01:42:20.791305 | Data as of: 2025-12-31 | Powered by Claude AI